科拓生物
(300858)
| 流通市值：29.17亿 | | | 总市值：40.55亿 |
| 流通股本：1.90亿 | | | 总股本：2.63亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 210,451,392.39 | 108,635,367.47 | 130,122,749.32 | 92,674,705.58 |
| 应收票据及应收账款 | 68,938,325.42 | 56,473,758.3 | 68,372,501.01 | 57,927,622.21 |
| 其中：应收票据 | 155,766 | - | - | 2,168,758.73 |
| 应收账款 | 68,782,559.42 | 56,473,758.3 | 68,372,501.01 | 55,758,863.48 |
| 预付款项 | 21,716,780.33 | 9,812,714.38 | 13,039,320.38 | 14,798,743.13 |
| 其他应收款合计 | 635,537.02 | 1,165,043.72 | 1,124,389.79 | 2,010,382.24 |
| 存货 | 42,808,856.93 | 46,599,458.64 | 33,866,230.33 | 34,601,891.4 |
| 一年内到期的非流动资产 | 585,996,744.32 | 425,496,669.38 | 346,458,140.05 | 333,104,746.87 |
| 其他流动资产 | 16,233,861.86 | 9,790,595.54 | 6,645,675.56 | 15,405,174.49 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,073,509,005.13 | 954,705,006.67 | 867,833,525.92 | 860,670,937.15 |
| 非流动资产: | | | | |
| 长期股权投资 | 12,274,690.77 | 2,334,840.72 | 2,406,997.87 | 2,130,437.52 |
| 其他权益工具投资 | 1,231,554 | 1,231,554 | 1,231,554 | 1,231,554 |
| 固定资产 | 373,903,734.32 | 372,861,360.1 | 344,316,124.53 | 199,979,882.17 |
| 在建工程 | 234,009,714.18 | 172,069,465.9 | 131,754,289 | 237,036,516.94 |
| 使用权资产 | 3,169,064.43 | 3,767,245.24 | 4,709,618.28 | 4,860,639.59 |
| 无形资产 | 55,075,370.81 | 48,326,185.45 | 48,804,410.04 | 49,287,442.16 |
| 商誉 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 |
| 长期待摊费用 | 1,681,798.1 | 2,312,472.39 | 2,312,472.44 | 2,312,472.39 |
| 递延所得税资产 | 4,506,464.62 | 5,360,630.94 | 4,395,334.72 | 4,556,513.43 |
| 其他非流动资产 | 170,785,992.02 | 350,715,598.55 | 441,001,582.21 | 454,877,863.23 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 858,551,717.68 | 960,892,687.72 | 982,845,717.52 | 958,186,655.86 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,932,060,722.81 | 1,915,597,694.39 | 1,850,679,243.44 | 1,818,857,593.01 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 56,960,199.4 | 47,727,805.31 | 23,528,022.55 | 20,765,639.2 |
| 应付账款 | 56,960,199.4 | 47,727,805.31 | 23,528,022.55 | 20,765,639.2 |
| 合同负债 | 15,485,311.36 | 23,126,832.19 | 16,137,094.96 | 14,806,984.25 |
| 应付职工薪酬 | 4,274,354.84 | 12,251,262.35 | 4,778,476.65 | 4,890,667.97 |
| 应交税费 | 12,704,261.93 | 7,181,533.09 | 5,345,268.58 | 4,641,344.9 |
| 其他应付款合计 | 2,858,268.96 | 3,024,240.07 | 1,912,716.05 | 20,078,249.72 |
| 应付股利 | - | - | - | 17,183,107.65 |
| 一年内到期的非流动负债 | 599,282.3 | 559,930.57 | 607,154.99 | 600,889.46 |
| 其他流动负债 | 1,232,791.81 | 2,316,912.77 | 1,271,835.15 | 1,177,352.56 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 94,114,470.6 | 96,188,516.35 | 53,580,568.93 | 66,961,128.06 |
| 非流动负债: | | | | |
| 租赁负债 | 2,929,171.5 | 3,225,216.41 | 4,142,369.16 | 4,277,504.53 |
| 递延收益 | 23,083,905.18 | 25,142,849.04 | 26,851,936.62 | 8,465,554.91 |
| 递延所得税负债 | 1,292,259.87 | 1,473,316.7 | 1,436,786.57 | 1,655,036.61 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 27,305,336.55 | 29,841,382.15 | 32,431,092.35 | 14,398,096.05 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 121,419,807.15 | 126,029,898.5 | 86,011,661.28 | 81,359,224.11 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 263,495,118 | 263,495,118 | 263,495,118 | 263,495,118 |
| 资本公积 | 1,107,785,475.46 | 1,107,041,979.46 | 1,105,307,155.46 | 1,105,813,678.79 |
| 其他综合收益 | 30.47 | 31.32 | -202.65 | - |
| 盈余公积 | 57,702,020.68 | 57,702,020.68 | 40,351,705.04 | 40,351,705.04 |
| 未分配利润 | 381,658,271.05 | 361,328,646.43 | 355,513,806.31 | 327,837,867.07 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,810,640,915.66 | 1,789,567,795.89 | 1,764,667,582.16 | 1,737,498,368.9 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,810,640,915.66 | 1,789,567,795.89 | 1,764,667,582.16 | 1,737,498,368.9 |
| 负债和股东权益合计 | 1,932,060,722.81 | 1,915,597,694.39 | 1,850,679,243.44 | 1,818,857,593.01 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-30 | 2024-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |